Mar 22, 2023 / 12:00AM GMT
Jackie Fairley - Starpharma Holdings Limited - CEO
Okay. Fine. Well, thank you, and thank you, everyone, for joining this morning. What I'm going to do this morning is to give a really brief overview of Starpharma's business. Obviously, time is somewhat limited, and I'm going to focus in on some -- particularly on our DEP platform and particularly some new developments in that area with one of our AstraZeneca collaborative programs AZD0466.
Just by way of overview in the first instance, just a snapshot of Starpharma. Starpharma is a company which is founded on an innovative platform called dendrimers, and we're applying those in a couple of different ways. We use them to deliver drugs and so we have developed a very valuable and innovative platform, which we refer to as DEP. And I'll talk in some detail about some of those partnerships we have developed.
Because of this platform, we've been able to develop a deep portfolio of high-value assets. And we have through our DEP platform, formed partnerships with a number of leading global companies, including three of the top 10 pharmaceutical
Starpharma Holdings Ltd at ASX Small and Mid-Cap Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot